Skip to main content
. 2021 Jan 5;5(1):113–121. doi: 10.1182/bloodadvances.2020003628

Table 1.

Characteristics of the 10 included studies

Study year Study characteristics Study population MPN Follow-up, y Antithrombotic treatment Reference
1991 Retrospective cohort N = 103 ET Mean 4.8 Antiplatelet ± cytoreduction (N = 74) 24
Single center Age: 9-88 y Cytoreduction only (N = 15)
Italy ♀/♂: 59/44 No treatment (N = 14)
2002 Retrospective cohort N = 118 ET Median 10 Antiplatelet ± cytoreduction (N = 118) 25
Single center Age: mean 62 y
Italy ♀/♂: 69/49
2008 Retrospective cohort N = 494 ET, PV Median 5.3 Antiplatelet ± cytoreduction (N = 351) 26
Multicenter Age: median 62 y VKA ± cytoreduction (N = 79)
Italy ♀/♂: 255/239 VKA + antiplatelet ± cytoreduction (N = 11)
Cytoreduction only (N = 40)
No treatment (N = 13)
2011 Retrospective cohort N = 44 ET, PV, MF, Unclassified Median 5.8 Antiplatelet only (N = 6) 27
Single center Age: median 48 y VKA only (N = 9)
Netherlands ♀/♂: 31/13 VKA + antiplatelet (N = 6)
No treatment (N = 23)
2016 Retrospective cohort N = 181 ET, PV, PMF Median 3.2 Antiplatelet + cytoreduction (N = 6) 28
Multicenter Age: median 48 y Anticoagulation ± cytoreduction (N = 156)
Multinational ♀/♂: 118/63 Anticoagulation + antiplatelet ± cytoreduction (N = 10)
Cytoreduction only (N = 8)
No treatment (N = 1)
2016 Retrospective cohort N = 206 ET, PV, PMF Median 2.6 Antiplatelet ± cytoreduction (N = 11) 29
Multicenter Age: median 72 y Anticoagulation ± cytoreduction (N = 163)
Multinational ♀/♂: 114/92 Anticoagulation + antiplatelet ± cytoreduction (N = 19)
Cytoreduction only (N = 9)
No treatment (N = 5)
2017 Prospective cohort N = 25 ET, PV Median 2.1 DOAC ± cytoreduction (N = 25) 30
Single center Age: median 75 y
France ♀/♂: 12/13
2018 Case-series N = 14 ET, PV, Unclassified Median 7.4 VKA ± cytoreduction (N = 9) 31
Single center Age: mean 47 y Antiplatelet ± cytoreduction (N = 2)
Northern Ireland ♀/♂: 11/3 VKA + antiplatelet ± cytoreduction (N = 3)
No treatment (N = 2)
2019 Retrospective cohort N = 78 ET, PV, MF Median 5.4 Anticoagulation ± cytoreduction (N = 71) 32
Single center Age: median 53 y No anticoagulation (N = 7)
Germany ♀/♂: 57 /25
2020 Retrospective cohort N = 32 ET, PV, MF, Unclassified Median 2.1 33
Single center Age: median 50 y DOAC + cytoreduction (N = 28)
United Kingdom ♀/♂: 18/14 DOAC + antiplatelet (N = 4)

DVT, deep vein thrombosis; PV, polycythemia vera.